Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aurinia sinks on Phase IIb lupus nephritis results

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) lost more half its value Monday after reporting data from the Phase IIb AURA-LV study of voclosporin ( LX211) to treat active lupus nephritis (LN). Although

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE